-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the pharmaceutical industry, with the fierce market competition in recent years, in order to enhance competitiveness, more and more pharmaceutical companies have sold the company's non-core businesses to focus on the main business and develop better
.
In recent news, Renfu Pharmaceutical announced that it intends to liquidate its 2.
52% of Huatai Insurance shares held by 1.
026 billion yuan, corresponding to 102 million shares, and the transfer price is 1.
026 billion yuan
.
The transferee this time is "Anda"
.
It is understood that as early as August 1996 when Huatai Insurance conducted an angel round of financing, Renfu Medicine had participated in it
.
In 2015, Renfu Pharmaceutical issued an asset announcement, announcing the formation of a consortium with Junzheng Group and Junzheng Chemical, and proposed to transfer the shares of Huatai Insurance listed on the Beijing Stock Exchange, and said that the investment would be beneficial to its construction of medical service projects that integrate medical care and care.
, To form strategic cooperation with insurance companies through the development of high-end medical services through commercial insurance
.
However, since the equity change was approved in 2018, the two parties have not had a clear and coordinated follow-up
.
The analysis believes that perhaps because insurance and medicine are relatively large fields, they have high professional barriers, and there is a gap in the depth of understanding of the two fields
.
Regarding the purpose of this equity transfer, Renfu Medicine stated that it is to implement the "refocusing focus", to promote business focus on asset optimization, and to gradually withdraw from sub-sectors where the competitive advantage is not obvious or the synergy is weak, and it has successively sold medical services , Gender health and other business-related assets
.
According to data, Renfu Medicine's business scope includes drug research and development, biotechnology research and development, and investment management in the pharmaceutical industry and medical institutions.
In the early years, it also deployed reproductive health, environmental protection, real estate, finance and other fields, but it has not been realized.
Obvious synergy value, the proportion of benefit is relatively low
.
In order to optimize the capital structure, in 2017, Renfu Medicine proposed to implement the strategy of "refocusing and focusing", while focusing on the main business, while carrying out the divestiture of non-core businesses and assets
.
Subsequently, Renfu Pharmaceutical successively divested Henan Renfu, Sichuan Renfu and other regional pharmaceutical commercial assets, Zhongyuan Ruide and other non-core pharmaceutical companies, and a number of medical service organizations.
Today, it will continue to divest insurance assets.
.
Renfu Medicine's 2021 third quarter report showed that the company's main operating income was 14.
861 billion yuan, a year-on-year increase of 0.
1%; the net profit attributable to the parent was 1.
094 billion yuan, a year-on-year increase of 78.
55%
.
It is worth mentioning that, in addition to Renfu Pharmaceutical’s shareholding in Tsinghuatai Insurance, Tianfeng Securities also announced recently that its controlling subsidiary, Tianfeng Tianrui Investment Co.
, Ltd.
, intends to liquidate all of its holdings in Huatai Insurance.
The ratio is 2.
52% to 4.
45%, the price is 1.
808 billion yuan, and the transferee is also "Anda
.
" Chubb is an insurance group company registered in the United States, with many insurance and reinsurance companies around the world, and has been profitable for the past three years
.
As of the end of 2020, Chubb North America’s paid-in capital is approximately US$14.
6 billion, total assets are approximately US$55.
9 billion, and net assets are approximately US$35.
9 billion.
In 2020, revenue is approximately US$1.
7 billion and net profit is approximately US$1.
4 billion.
.
At present, "Anda" companies have a total of 47% of Huatai Insurance.
If the two equity transfers are completed, the "Anda" will hold more than half of the shares, and it will become the largest shareholder
.
As of September 30, Huatai Insurance's total assets were 60.
41 billion yuan, net assets were 17.
307 billion yuan, and the third quarter of 2021 revenue was 12.
407 billion yuan, net profit was 971 million yuan, and net profit attributable to the parent was 875 million yuan
.
.
In recent news, Renfu Pharmaceutical announced that it intends to liquidate its 2.
52% of Huatai Insurance shares held by 1.
026 billion yuan, corresponding to 102 million shares, and the transfer price is 1.
026 billion yuan
.
The transferee this time is "Anda"
.
It is understood that as early as August 1996 when Huatai Insurance conducted an angel round of financing, Renfu Medicine had participated in it
.
In 2015, Renfu Pharmaceutical issued an asset announcement, announcing the formation of a consortium with Junzheng Group and Junzheng Chemical, and proposed to transfer the shares of Huatai Insurance listed on the Beijing Stock Exchange, and said that the investment would be beneficial to its construction of medical service projects that integrate medical care and care.
, To form strategic cooperation with insurance companies through the development of high-end medical services through commercial insurance
.
However, since the equity change was approved in 2018, the two parties have not had a clear and coordinated follow-up
.
The analysis believes that perhaps because insurance and medicine are relatively large fields, they have high professional barriers, and there is a gap in the depth of understanding of the two fields
.
Regarding the purpose of this equity transfer, Renfu Medicine stated that it is to implement the "refocusing focus", to promote business focus on asset optimization, and to gradually withdraw from sub-sectors where the competitive advantage is not obvious or the synergy is weak, and it has successively sold medical services , Gender health and other business-related assets
.
According to data, Renfu Medicine's business scope includes drug research and development, biotechnology research and development, and investment management in the pharmaceutical industry and medical institutions.
In the early years, it also deployed reproductive health, environmental protection, real estate, finance and other fields, but it has not been realized.
Obvious synergy value, the proportion of benefit is relatively low
.
In order to optimize the capital structure, in 2017, Renfu Medicine proposed to implement the strategy of "refocusing and focusing", while focusing on the main business, while carrying out the divestiture of non-core businesses and assets
.
Subsequently, Renfu Pharmaceutical successively divested Henan Renfu, Sichuan Renfu and other regional pharmaceutical commercial assets, Zhongyuan Ruide and other non-core pharmaceutical companies, and a number of medical service organizations.
Today, it will continue to divest insurance assets.
.
Renfu Medicine's 2021 third quarter report showed that the company's main operating income was 14.
861 billion yuan, a year-on-year increase of 0.
1%; the net profit attributable to the parent was 1.
094 billion yuan, a year-on-year increase of 78.
55%
.
It is worth mentioning that, in addition to Renfu Pharmaceutical’s shareholding in Tsinghuatai Insurance, Tianfeng Securities also announced recently that its controlling subsidiary, Tianfeng Tianrui Investment Co.
, Ltd.
, intends to liquidate all of its holdings in Huatai Insurance.
The ratio is 2.
52% to 4.
45%, the price is 1.
808 billion yuan, and the transferee is also "Anda
.
" Chubb is an insurance group company registered in the United States, with many insurance and reinsurance companies around the world, and has been profitable for the past three years
.
As of the end of 2020, Chubb North America’s paid-in capital is approximately US$14.
6 billion, total assets are approximately US$55.
9 billion, and net assets are approximately US$35.
9 billion.
In 2020, revenue is approximately US$1.
7 billion and net profit is approximately US$1.
4 billion.
.
At present, "Anda" companies have a total of 47% of Huatai Insurance.
If the two equity transfers are completed, the "Anda" will hold more than half of the shares, and it will become the largest shareholder
.
As of September 30, Huatai Insurance's total assets were 60.
41 billion yuan, net assets were 17.
307 billion yuan, and the third quarter of 2021 revenue was 12.
407 billion yuan, net profit was 971 million yuan, and net profit attributable to the parent was 875 million yuan
.
